Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Fatima de la Cruz-Vicente"'
Autor:
Mariano Provencio, Luis de la Cruz-Merino, Delvys Rodriguez-Abreu, Tomás Álvaro, Marylène Lejeune, Carlos Jiménez-Cortegana, Natalia Palazón-Carrión, Alejandro Martin Garcia-Sancho, Esteban Nogales-Fernandez, Fernando Carnicero-González, Eduardo Ríos-Herranz, Fatima de la Cruz-Vicente, Guillermo Rodríguez-García, Rubén Fernández-Álvarez, Antonio Rueda Dominguez, Maria Casanova-Espinosa, Natividad Martínez-Banaclocha, Josep Gumà-Padrò, José Gómez-Codina, Jorge Labrador, Antonio Salar-Silvestre, Laura Galvez-Carvajal, Margarita Sánchez-Beato, María Guirado-Risueño, Pablo Espejo-García, Victor Sánchez-Margalet
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Background The search for immunological markers with ability of predicting clinical outcome is a priority in lymphomas, and in cancer in general. It is well known that some immunomodulatory cells, such as myeloid derived suppressor cells (MDSCs) or r
Externí odkaz:
https://doaj.org/article/b89f60e62bf043c59fe379aa70ec66e3
Autor:
Lourdes Hontecillas-Prieto, Daniel J. García-Domínguez, Natalia Palazón-Carrión, Alejandro Martín García-Sancho, Esteban Nogales-Fernández, Carlos Jiménez-Cortegana, María L. Sánchez-León, Silvia Silva-Romeiro, Rocío Flores-Campos, Fernando Carnicero-González, Eduardo Ríos-Herranz, Fátima de la Cruz-Vicente, Guillermo Rodríguez-García, Rubén Fernández-Álvarez, Natividad Martínez-Banaclocha, Josep Gumà-Padrò, José Gómez-Codina, Antonio Salar-Silvestre, Delvys Rodríguez-Abreu, Laura Gálvez-Carvajal, Jorge Labrador, María Guirado-Risueño, Mariano Provencio-Pulla, Margarita Sánchez-Beato, Lejeune Marylene, Tomás Álvaro-Naranjo, María Casanova-Espinosa, Antonio Rueda-Domínguez, Víctor Sánchez-Margalet, Luis de la Cruz-Merino
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundDiffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma worldwide. DLBCL is an aggressive disease that can be cured with upfront standard chemoimmunotherapy schedules. However, in approximately 35-40% of the patients D
Externí odkaz:
https://doaj.org/article/212d6baeaf2d4c8bb7bf0ab05ba40793
Autor:
Jorge Gomez, Guillermo Rodríguez, Christina Quero Blanco, Natalia Palazón-Carrión, Fatima de la Cruz-Vicente, Delvys Rodriguez-Abreu, Antonio Salar Silvestre, Fernando González, Pablo Espejo García, Antonio Rueda Dominguez, Concepción Nicolás, Eduardo Ríos Herranz, Luis Merino, Josep Guma, M. Guirado, Esteban Nogales Fernández, Mariano Provencio-Pulla, José Gómez-Codina, Natividad Martínez-Banaclocha, Alejandro Martín
Publikováno v:
JOURNAL OF CLINICAL ONCOLOGY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
8019 Background: Lenalidomide is an immunomodulatory drug that could reverse rituximab refractoriness in lymphoma patients (pts). We conducted an open label multicenter phase 2 trial testing the efficacy and toxicity of a combination of lenalidomide
Autor:
Fatima De La Cruz Vicente, Julie Meade, Conny Nippgen, Sylvain Choquet, Miguel Albendea Canales, Marie Maerevoet, Brendan Wrigley, John Kuruvilla, Jason B. Kaplan, Humphrey Gardner, Rene-Olivier Casasnovas, Catherine Thieblemont, Marissa Devlin, Sharon Shacham, Josée M. Zijlstra, George A. Follows, Michael Kauffman, Eric Van Den Neste, Jason R. Westin, Paolo Caimi, Brian T. Hill
Publikováno v:
Cancer Research. 77:CT132-CT132
Intro: Patients with DLBCL after at least two lines of therapy have limited effective treatments options. The nuclear export protein exportin 1 (XPO1) is upregulated in hematologic malignancies including DLBCL with pleiotropic effects on tumorigenesi